A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 15, 2005

Primary Completion Date

May 22, 2012

Study Completion Date

September 30, 2024

Conditions
Glioma
Interventions
DRUG

LY2157299

Administered orally

DRUG

Lomustine

Administered orally

Trial Locations (4)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01682187 - A Dose-Escalation Study in Participants With Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter